Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2005

01-12-2005 | Article

Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats

Authors: M. Alves, V. C. Calegari, D. A. Cunha, M. J. A. Saad, L. A. Velloso, E. M. Rocha

Published in: Diabetologia | Issue 12/2005

Login to get access

Abstract

Aims/hypothesis

To assess the involvement of the AGE-specific receptor (AGER, also known as RAGE) axis and nuclear factor kappa-B (NFKB, also known as NF-kappaB) activation in the development of lacrimal gland and tear film dysfunction in diabetes, the present study evaluated: (1) lacrimal gland and tear film alterations in diabetic rats; and (2) the expression of AGE, AGER and NFKB in ocular tissues of normoglycaemic and diabetic rats.

Materials and Methods

Diabetes was induced in male Wistar rats with intravenous streptozotocin. Tear secretion parameters were measured and NFKB expression was evaluated in lacrimal glands of control and diabetic rats by western blot. Immunohistochemistry with confocal microscopy was used to assess AGE, AGER and NFKB expression in lacrimal glands of both groups.

Results

Lacrimal gland weight and tear film volume were lower in diabetic than in control rats (p=0.01 and 0.02, respectively). IL1B and TNF concentrations in tears were higher in diabetic than in control rats (p=0.007 and 0.02, respectively). NFKB protein was identified in rat cornea, conjunctiva and lacrimal glands. AGE, AGER and NFKB expression were greater in lacrimal glands of diabetic than in those of control rats.

Conclusions/interpretation

Diabetes induces significant alterations in rat lacrimal gland structure and secretion. The higher expression of AGE, AGER and NFKB in lacrimal glands of diabetic rats suggests that these factors are involved in signalling and in subsequent inflammatory alterations related to dry eye in diabetes mellitus.
Literature
1.
Ramos-Remus C, Suarez-Almazor M, Russell AS (1994) Low tear production in patients with diabetes mellitus is not due to Sjogren's syndrome. Clin Exp Rheumatol 12:375–380PubMed
2.
Seifart U, Strempel I (1994) The dry eye and diabetes mellitus. Ophthalmologe 91:235–239PubMed
3.
Goebbels M (2000) Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol 84:19–21CrossRefPubMed
4.
Dogru M, Katakami C, Inoue M (2001) Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 108:586–592CrossRefPubMed
5.
Hyndiuk RA, Kazarian EL, Schultz RO, Seideman S (1977) Neurotrophic corneal ulcers in diabetes mellitus. Arch Ophthalmol 95:2193–2196PubMed
6.
Ishida N, Rao GN, del Cerro M, Aquavella JV (1984) Corneal nerve alterations in diabetes mellitus. Arch Ophthalmol 102:1380–1384PubMed
7.
Azar DT, Spurr-Michaud SJ, Tisdale AS, Gipson IK (1992) Altered epithelial-basement membrane interactions in diabetic corneas. Arch Ophthalmol 110:537–540PubMed
8.
McNamara NA, Brand RJ, Polse KA, Bourne WM (1998) Corneal function during normal and high serum glucose levels in diabetes. Invest Ophthalmol Vis Sci 39:3–17PubMed
9.
Rocha EM, de MLMH, Carvalho CR et al (2000) Characterization of the insulin-signaling pathway in lacrimal and salivary glands of rats. Curr Eye Res 21:833–842CrossRefPubMed
10.
Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129–146CrossRefPubMed
11.
Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50:2792–2808PubMedCrossRef
12.
Portero-Otin M, Pamplona R, Bellmunt MJ et al (2002) Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 51:1535–1542PubMedCrossRef
13.
Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138–151PubMed
14.
Zoukhri D, Hodges RR, Byon D, Kublin CL (2002) Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia. Invest Ophthalmol Vis Sci 43:1429–1436PubMed
15.
Rocha EM, Wickham LA, Huang Z et al (1998) Presence and testosterone influence on the levels of anti- and pro-inflammatory cytokines in lacrimal tissues of a mouse model of Sjogren's syndrome. Adv Exp Med Biol 438:485–491PubMed
16.
Solomon A, Dursun D, Liu Z et al (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42:2283–2292PubMed
17.
Stitt AW, Moore JE, Sharkey JA et al (1998) Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci 39:2517–2523PubMed
18.
Kalfa TA, Gerritsen ME, Carlson EC et al (1995) Altered proliferation of retinal microvascular cells on glycated matrix. Invest Ophthalmol Vis Sci 36:2358–2367PubMed
19.
Moore TC, Moore JE, Kaji Y et al (2003) The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 44:4457–4464CrossRefPubMed
20.
Howes KA, Liu Y, Dunaief JL et al (2004) Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 45:3713–3720CrossRefPubMed
21.
Hammes HP, Hoerauf H, Alt A et al (1999) N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 40:1855–1859PubMed
22.
Ahmed N, Thornalley PJ, Dawczynski J et al (2003) Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 44:5287–5292CrossRefPubMed
23.
Das BK, Sun TX, Akhtar NJ et al (1998) Fluorescence and immunochemical studies of advanced glycation-related lens pigments. Invest Ophthalmol Vis Sci 39:2058–2066PubMed
24.
Saxena P, Saxena AK, Cui XL et al (2000) Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. Invest Ophthalmol Vis Sci 41:1473–1481PubMed
25.
Rakieten N, Rakieten ML, Nadkarni MV (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91–98
26.
Junod A, Lambert AE, Orci L et al (1967) Studies of the diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 126:201–205PubMed
27.
Herzog V, Sies H, Miller F (1976) Exocytosis in secretory cells of rat lacrimal gland. Peroxidase release from lobules and isolated cells upon cholinergic stimulation. J Cell Biol 70:692–706CrossRefPubMed
28.
Stoppiglia LF, Nogueira TA, Leite AR et al (2002) Protective effect of d-glucose, l-leucine and fetal calf serum against oxidative stress in neonatal pancreatic islets. Biochim Biophys Acta 1588:113–118PubMed
29.
Vaisse C, Halaas JL, Horvath CM et al (1996) Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 14:95–97CrossRefPubMed
30.
Koito W, Araki T, Horiuchi S, Nagai R (2004) Conventional antibody against Nepsilon-(carboxymethyl)lysine (CML) shows cross-reaction to Nepsilon-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody. J Biochem (Tokyo) 136:831–837
31.
Kaji Y, Usui T, Oshika T et al (2000) Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 41:362–368PubMed
32.
Bromberg BB, Welch MH (1985) Lacrimal protein secretion: comparison of young and old rats. Exp Eye Res 40:313–320CrossRefPubMed
33.
Adeghate E, Ponery A, Hameed R (2005) Notes on the effect of diabetes mellitus on the morphology and function of the rat lacrimal gland. The Ocular Surface 3: S42 [Abstract]
34.
Paliwal A, Srikantan AQ, Stephano PK (2005) Androgen, estrogen and thyroid hormones repress tear peroxidase gene in lacrimal gland of hamster. The Ocular Surface 3:S102 [Abstract]
35.
Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901CrossRefPubMed
36.
Degenhardt TP, Alderson NL, Arrington DD et al (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939–950CrossRefPubMed
37.
Kern TS, Tang J, Mizutani M et al (2000) Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 41:3972–3978PubMed
38.
Peponis V, Papathanasiou M, Kapranou A et al (2002) Protective role of oral antioxidant supplementation in ocular surface of diabetic patients. Br J Ophthalmol 86:1369–1373CrossRefPubMed
Metadata
Title
Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats
Authors
M. Alves
V. C. Calegari
D. A. Cunha
M. J. A. Saad
L. A. Velloso
E. M. Rocha
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0010-9

Other articles of this Issue 12/2005

Diabetologia 12/2005 Go to the issue

Letter

Comment on: McClung JA, Naseer N, Saleem M et al (2005) Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia 48:345–350

Original Paper

Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta

Erratum

A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes

Article

Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects

Article

Gene expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance

For debate

Contraindications can damage your health—is metformin a case in point?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits